Kenya

5.

Le Fonds mondial approuve le financement de deux subventions nationales, une subvention multipays et 10 demandes de fonds de contrepartie

7 May 2018
Le Fonds mondial investit 6 millions de dollars dans l’Initiative régionale d’élimination du paludisme en Amérique centrale et sur l’île d’Hispaniola
7.

Global Fund Board approves funding for two country grants, a multi-country grant and 10 matching funds requests

24 Apr 2018
Fund invests $6 million in the Regional Malaria Elimination Initiative in Mesoamerica and Hispaniola
5.

Kenya Red Cross Society has been a successful Global Fund PR

7 Mar 2018
Supportive leadership, effective support for its SRs are among the reasons why

The Kenya Red Cross Society (KRCS) has been a successful principal recipient (PR) for an HIV grant (KEN-H-KRCS) entitled “The road towards an HIV free society” based on the ratings of the grant over the years.

4.

Small-scale fraud found in training activities and meetings related to a Global Fund TB grant to Kenya

20 Feb 2018
Disciplinary action taken against two employees

An investigation by the Office of the Inspector General (OIG) into a TB grant to Kenya has identified $62,557 in non-compliant expenditures. A report on the investigation was released on 9 February 2017.

3.

Le CTEP loue la demande de financement TB/VIH du Kenya au Fonds mondial pour l’attention portée aux populations clés et aux droits de l’homme

31 Jan 2018
La décentralisation est qualifiée à la fois d’occasion et de défi
5.

TRP praises Kenya's TB/HIV funding request to the Global Fund for its sensitivity to key populations and human rights

23 Jan 2018
Devolution cited as both an opportunity and a challenge
1.

Les cibles nationales ambitieuses de mise sous traitement ne se retrouvent souvent pas dans les cadres de résultats des subventions, selon le CAS

20 Dec 2017
La cause : « les limites budgétaires de la période d’allocation 2017/2019 »
Le CAS appelle à la tenue urgente de discussions interinstitutions incluant les gouvernements donateurs
1.

Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says

13 Dec 2017
The reason? “Limitations of budgets in the 2017-2019 allocations period”
GAC calls for urgent inter-agency discussions, with donor governments included

In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation

2.

Le Fonds mondial bénéficiera d’un accord décisif sur les prix des antirétroviraux

11 Oct 2017
La combinaison thérapeutique à dose fixe de dernière génération coûtera 75 dollars par patient par an

Dans ce qui a été salué comme une « percée » et susceptible de « changer la donne », la Fondation Bill et Melinda Gates et deux fabricants de médicaments génériques ont conclu un accord de prix qui entraînera des économies significatives au niveau des coûts des antirétroviraux.

3.

Global Fund to benefit from “breakthrough” ARV pricing agreement

3 Oct 2017
State-of-the-art fixed dose combination regimen will cost $75 per patient per year

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.

Pages

Subscribe to Kenya